Waldenstroem macroglobulinemia · 4 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Ibrutinib and Rituximab Variant #02 | — | R 157 847 | 28d | — | — | ~8 | ~R 822 396 PFS proxy · indirect | 2 |
Fludarabine and Rituximab (FR) Variant #01 | — | R 34 157 | 28d | — | — | ~6 | ~R 204 943 indirect | — |
Bendamustine and Rituximab (BR) Variant #01 | — | R 33 874 | 28d | ~39.6 mo | — | ~8 | ~R 270 994 PFS proxy · indirect | 18 |
Rituximab monotherapy Variant #09 Partial | — | — | 28d | ~20.3 mo | — | ~1 | — | 2 |
4 of 4 regimens shown